LianBio Q2 2023 net loss narrows to $21.6M; cash $267.3M; mavacamten NDA under priority review in China

LianBio

2023-Q2 EPS reported -$0.43 vs consensus -$0.29 ▼ miss (-46.5%)

Net loss $21.6M in Q2 2023 vs $42.4M in Q2 2022; R&D expenses fell to $9.5M from $28.6M.
Cash, equivalents and marketable securities $267.3M at June 30, 2023; runway into first half 2025.
Mavacamten NDA accepted with priority review by China NMPA; approved in Singapore and Macau.
Phase 3 EXPLORER-CN met primary endpoint; data to be presented at ESC Congress 2023.
TP-03 Phase 3 LIBRA fully enrolled; infigratinib Phase 2a in gastric cancer showed 25% ORR.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LianBio reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 14, 2023, LianBio (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

LianBio filing history →

Source: SEC EDGAR

accession 0001831283-23-000107

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.